Semaglutide oral - Novo Nordisk

Drug Profile

Semaglutide oral - Novo Nordisk

Alternative Names: GLP-1-SNAC; NN-9924; NNC0113-0217; OG-217SC

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 12 Jul 2018 Novo Nordisk completes the phase III PIONEER 10 trial for Type-2 diabetes mellitus in Japan (PO) (NCT03015220)
  • 10 Jul 2018 Novo Nordisk completes a phase I trial for Type 2 diabetes mellitus in Germany (PO) (NCT03466567)
  • 28 Jun 2018 Safety and efficacy data from the phase III PIONEER 3 trial in Type-2 diabetes mellitus released by Novo Nordisk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top